Abstract: Gastrointestinal stromal tumor (GIST) is originated from the gastrointestinal mesenchymal stem cells, composed of undifferentiated or pluripotent spindle and epithelioid cells, often occurs in the whole range of the gastrointestinal tract and occasionally in the omentum, mesenterium and other areas which are outside of digestive tract. The treatment is difficult due to broadspectrum biological behaviour of GIST, while surgery may be the only potential method for curing GIST with a risk of recurrence. Currently, there is still not an evaluative standard in the choice of surgery or imatinib therapy as well as the risk of recurrence. The F/NIH consensus,  Armed Forces Institute of Pathology (AFIP) standard, modified standard of National Institutes of Health(NIH) and consensus of mathematical model which have been widely used cannot accurately evaluate risk probability of recurrence, so the current researches have focused on the postoperative risk assessment for GIST. In recent years, the nomogram model has been applied to predict the risk of GIST recurrence by some scholars, with the better outcomes.